A Lamarca1, O Abdel-Rahman1,2, I Salu1, M G McNamara1,3, J W Valle1,3, R A Hubner4. 1. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. 2. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 3. Institute of Cancer Sciences, Manchester Academic Health Science Centre (MAHSC), University of Manchester, Manchester, UK. 4. Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, UK. richard.hubner@christie.nhs.uk.
Abstract
BACKGROUND: Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are potential clinical biomarkers. METHODS: Survival and toxicity data for patients with HCC treated with sorafenib at the Christie NHS Foundation Trust from 11/09 to 02/15 were collected retrospectively. RESULTS: Eighty-five eligible patients were identified. The most common grade 3 or 4 treatment-related toxicities were hypertension (HTN, 45 %), fatigue (8 %), and hand-foot syndrome (HFS, 8 %). Any-grade HFS and/or worsening HTN (HFS/HTN) were experienced by 58 % of patients. Estimated median progression-free and overall survival (OS) were 4.6 (95 % CI 2.8-5.2) and 6.5 (95 % CI 4.9-8.01) months, respectively. Child-Pugh score (p value <0.001) and the development of HFS/HTN were independent prognostic factors impacting on OS on multivariable analysis. Patients who developed HFS/HTN had median OS of 8.2 months (95 % CI 6.5-12.4) compared with 4.1 (95 % CI 2.7-5.4) for those without this toxicity (Hazard Ratio (HR) 0.4, 95 % CI 0.2-0.7, p value 0.003). The prognostic impact of HFS/HTN was confirmed by landmark analyses limited to patients who lived a minimum of 2 months (p value 0.019) or who developed HFS/HTN in the first 3 months of treatment (p value 0.006). CONCLUSION(S): The development of toxicities specific to sorafenib is associated with prolonged survival in a UK-based HCC patient series; prospective assessment of their significance is required.
BACKGROUND: Identification of patients with advanced HCC-deriving preferential benefit from sorafenib is desirable, and treatment-related adverse events are potential clinical biomarkers. METHODS: Survival and toxicity data for patients with HCC treated with sorafenib at the Christie NHS Foundation Trust from 11/09 to 02/15 were collected retrospectively. RESULTS: Eighty-five eligible patients were identified. The most common grade 3 or 4 treatment-related toxicities were hypertension (HTN, 45 %), fatigue (8 %), and hand-foot syndrome (HFS, 8 %). Any-grade HFS and/or worsening HTN (HFS/HTN) were experienced by 58 % of patients. Estimated median progression-free and overall survival (OS) were 4.6 (95 % CI 2.8-5.2) and 6.5 (95 % CI 4.9-8.01) months, respectively. Child-Pugh score (p value <0.001) and the development of HFS/HTN were independent prognostic factors impacting on OS on multivariable analysis. Patients who developed HFS/HTN had median OS of 8.2 months (95 % CI 6.5-12.4) compared with 4.1 (95 % CI 2.7-5.4) for those without this toxicity (Hazard Ratio (HR) 0.4, 95 % CI 0.2-0.7, p value 0.003). The prognostic impact of HFS/HTN was confirmed by landmark analyses limited to patients who lived a minimum of 2 months (p value 0.019) or who developed HFS/HTN in the first 3 months of treatment (p value 0.006). CONCLUSION(S): The development of toxicities specific to sorafenib is associated with prolonged survival in a UK-based HCC patient series; prospective assessment of their significance is required.
Authors: C A Bellera; N Penel; M Ouali; S Bonvalot; P G Casali; O S Nielsen; M Delannes; S Litière; F Bonnetain; T S Dabakuyo; R S Benjamin; J-Y Blay; B N Bui; F Collin; T F Delaney; F Duffaud; T Filleron; M Fiore; H Gelderblom; S George; R Grimer; P Grosclaude; A Gronchi; R Haas; P Hohenberger; R Issels; A Italiano; V Jooste; A Krarup-Hansen; C Le Péchoux; C Mussi; O Oberlin; S Patel; S Piperno-Neumann; C Raut; I Ray-Coquard; P Rutkowski; S Schuetze; S Sleijfer; E Stoeckle; M Van Glabbeke; P Woll; S Gourgou-Bourgade; S Mathoulin-Pélissier Journal: Ann Oncol Date: 2014-07-28 Impact factor: 32.976
Authors: Elisa Herraez; Elisa Lozano; Rocio I R Macias; Javier Vaquero; Luis Bujanda; Jesus M Banales; Jose J G Marin; Oscar Briz Journal: Hepatology Date: 2013-07-30 Impact factor: 17.425
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang Journal: J Clin Oncol Date: 2014-12-29 Impact factor: 44.544
Authors: R Diaz-Beveridge; G Bruixola; D Lorente; J Caballero; E Rodrigo; Á Segura; D Akhoundova; A Giménez; J Aparicio Journal: Clin Transl Oncol Date: 2017-08-11 Impact factor: 3.405